Study Description: This study will evaluate the effectiveness, safety, and tolerability of Suvorexant plus antidepressant therapy compared to placebo (A substance containing no medication) plus antidepressant therapy in patients diagnosed with Major Depressive Disprder with Residual Insomnia. The study will include both men and women 18 to 70 years of age. Study participation will last for 7 weeks.
Principal Investigator: William McCall
Eligibility Criteria: INCLUSION CRITERIA Subjects between 18 -70 years of age. Subjects with Major Depressive Disorder and Insomnia disorder. Subjects with no known sensitivity to Belsomra (suvorexant).
Compensation: No, subjects will not be compensated.
If you don't see specific studies that interest you, please submit your contact information for future studies.